Abubakari Sulemana Watara, Workneh Firehiwot, Asante Kwaku Poku, Hemler Elena C, Madzorera Isabel, Wang Dongqing, Ismail Abbas, Assefa Nega, Azemraw Temesgen, Lankoande Bruno, Nuhu Abdul Razak, Chukwu Angela, Mapendo Frank, Millogo Ourohiré, Olufemi Adedokun A, Okpara Daniel, Boudo Valentin, Mwanyika-Sando Mary, Berhane Yemane, Baernighausen Till, Oduola Ayoade, Vuai Said, Sie Ali, Soura Abdramane, Killewo Japhet, Tajudeen Raji, Fawzi Wafaie W, Smith Emily R
Research and Development Division, Kintampo Health Research Centre, Ghana Health Service, Kintampo North Municipality, Bono East Region, Ghana.
Department of Epidemiology and Biostatistics, Addis Continental Institute of Public Health, Addis Ababa, Ethiopia.
PLOS Glob Public Health. 2023 Jul 14;3(7):e0000713. doi: 10.1371/journal.pgph.0000713. eCollection 2023.
There is very limited data on the extent and determinants of COVID-19 vaccine hesitancy among adults living in sub-Saharan Africa since the global roll-out of vaccines began in 2021. This multi-country survey sought to investigate COVID-19 vaccine hesitancy and other predictors of readiness to get vaccinated. We conducted surveys among adults residing in nine urban and rural areas in Burkina Faso, Ethiopia, Ghana, Nigeria, and Tanzania in late 2021. Log binomial regression models were used to identify prevalence and factors associated with vaccine hesitancy and beliefs around COVID-19 misinformation. We completed a total of 2,833 interviews. Among all respondents, 9% had never heard of a COVID-19 vaccine, 12% had been vaccinated, and 20% knew someone else who had been vaccinated. The prevalence of vaccine hesitancy varied by country (Ethiopia 29%, Burkina Faso 33%, Nigeria 34%, Ghana 42%, Tanzania 65%), but not by rural or urban context. People who did not think the vaccine was safe or effective, or who were unsure about it, were more likely to be vaccine hesitant. Those who reported they did not have a trusted source of information about the vaccine (aPR: 1.25, 95% CI: 1.18,1.31) and those who thought the vaccine would not be made available to them within the year were more likely to be vaccine hesitant. Women were more likely to be vaccine hesitant (aPR: 1.31, 95% CI: 1.19,1.43) and believe COVID-19 falsehoods (aPR: 1.05, 95% CI: 1.02,1.08). The most commonly believed falsehoods were that the vaccine was developed too fast and that there was not enough information about whether the vaccine was effective or not. Educational campaigns targeted at misinformation and tailored to suit each country are recommended to build trust in COVID-19 vaccines and reduce hesitancy.
自2021年全球开始推广新冠疫苗以来,关于撒哈拉以南非洲地区成年人对新冠疫苗犹豫的程度及其决定因素的数据非常有限。这项多国调查旨在探究新冠疫苗犹豫情况以及其他接种疫苗意愿的预测因素。2021年末,我们在布基纳法索、埃塞俄比亚、加纳、尼日利亚和坦桑尼亚的9个城乡地区对成年人进行了调查。采用对数二项回归模型来确定与疫苗犹豫以及围绕新冠错误信息的信念相关的患病率和因素。我们总共完成了2833次访谈。在所有受访者中,9%从未听说过新冠疫苗,12%已接种疫苗,20%认识其他已接种疫苗的人。疫苗犹豫的患病率因国家而异(埃塞俄比亚29%、布基纳法索33%、尼日利亚34%、加纳42%、坦桑尼亚65%),但不受城乡背景影响。那些认为疫苗不安全或无效,或者对此不确定的人更有可能对疫苗持犹豫态度。那些报告称没有关于疫苗的可靠信息来源的人(调整后风险比:1.25,95%置信区间:1.18,1.31)以及那些认为疫苗在一年内无法提供给他们的人更有可能对疫苗持犹豫态度。女性更有可能对疫苗持犹豫态度(调整后风险比:1.31,95%置信区间:1.19,1.43)并相信新冠错误信息(调整后风险比:1.05,95%置信区间:1.02,1.08)。最常被相信的错误信息是疫苗研发太快以及关于疫苗是否有效没有足够信息。建议开展针对错误信息并根据每个国家情况量身定制的教育活动,以建立对新冠疫苗的信任并减少犹豫情绪。